Demineralized Bone Matrix Global Market Report 2025

The demineralized bone matrix market size has grown strongly in recent years. It will grow from $1.05 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. Growth during the historic period can be attributed to the rising incidence of orthopedic injuries, an increase in spinal fusion procedures, an expanding geriatric population, a growing preference for allografts, and a rise in sports-related injuries.

The demineralized bone matrix market size is expected to see strong growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Growth during the forecast period can be attributed to the increasing demand for minimally invasive surgeries, rising healthcare expenditures, greater awareness among surgeons and patients, an enhanced focus on biologics in orthopedics, and a growing number of outpatient surgical centers. Key trends expected in this period include advancements in regenerative medicine, the integration of demineralized bone matrix with stem cell therapies, the development of injectable DBM formats, a shift toward synthetic and hybrid grafts, and customization of DBM for specific applications.

The rising prevalence of orthopedic disorders is expected to drive the growth of the demineralized bone matrix (DBM) market in the coming years. Orthopedic disorders encompass conditions affecting the musculoskeletal system, including bones, joints, muscles, ligaments, tendons, and nerves. The demand for orthopedic treatments is growing due to the aging global population, as older adults are more susceptible to musculoskeletal conditions such as osteoarthritis, osteoporosis, and fractures. Demineralized bone matrix supports orthopedic care by promoting bone regeneration and healing, making it a vital component in spinal fusion, joint reconstruction, and fracture repair. It enhances recovery by providing an osteoinductive scaffold that encourages natural bone growth and improves surgical outcomes. For example, in August 2023, a survey by the Institute for Health Metrics and Evaluation, a US-based public health research organization, reported that 15% of individuals aged 30 and above had osteoarthritis in 2023, with the number expected to reach approximately 1 billion by 2050. Thus, the increasing prevalence of orthopedic disorders is fueling growth in the DBM market.

Leading companies in the demineralized bone matrix market are concentrating on developing advanced products like 3D-printed bone matrices, which allow for patient-specific bone grafts with enhanced precision, biocompatibility, and regenerative capability. A three-dimensional (3D) printed bone matrix is a scaffold or implant created using 3D printing technology to replicate the structural and functional properties of natural bone tissue. For example, in December 2022, Essent Biologics, a US-based biotechnology firm, introduced a micronized bone matrix designed specifically for 3D bioprinting and tissue engineering applications. This innovative product offers a standardized, finely ground demineralized bone matrix that can be easily integrated into bioinks and scaffolds. It promotes cellular attachment and growth, facilitating the production of biologically active, customized constructs that enhance the accuracy and effectiveness of regenerative treatments and bone repair approaches.

In September 2023, Globus Medical Inc., a US-based medical device company, merged with NuVasive Inc. for an undisclosed sum. Through this merger, Globus Medical seeks to strengthen its leadership position in the global spine and orthopedics market by incorporating NuVasive’s expertise in minimally invasive surgical techniques and advanced intraoperative technologies. NuVasive Inc., also based in the US, manufactures demineralized bone matrix (DBM) products under its Propel DBM brand.

Major players in the demineralized bone matrix market are Johnson & Johnson, Medtronic plc, Medline Industries LP, Stryker Corporation, Zimmer Biomet Holdings Inc., Arthrex Inc., Straumann AG, Globus Medical Inc., Integra LifeSciences Corporation, Halma plc, MTF Biologics, Exactech Inc., RTI Surgical, AlloSource, Cerapedics Inc., Keystone Dental Inc., Omnia Medical, Xtant Medical Holdings Inc., Hans Biomed Co. Ltd., and Bone Biologics Corp.

North America was the largest region in the demineralized bone matrix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in demineralized bone matrix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the demineralized bone matrix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Demineralized bone matrix (DBM) is an allograft bone product created by removing the mineral content from human bone, leaving the organic collagen matrix and growth factors intact. This process retains proteins such as bone morphogenetic proteins (BMPs), which aid in promoting new bone growth. DBM is widely used in orthopedic and dental surgeries to facilitate bone healing and regeneration.

The main types of demineralized bone matrix products include gel, putty, sponge, fiber, paste, and others. Gel DBM is a formulation where the demineralized bone matrix is suspended in a biocompatible carrier like glycerol, hyaluronic acid, or saline-based solutions, resulting in a moldable and injectable gel-like texture. The tissue sources for DBM include allograft and xenograft materials, and it is utilized in various medical procedures such as dental, craniomaxillofacial, spinal fusion, long bone surgeries, joint reconstruction, and more. The key end users are hospitals, ambulatory surgical centers, specialty clinics, and others.

The demineralized bone matrix market research report is one of a series of new reports that provides demineralized bone matrix market statistics, including demineralized bone matrix industry global market size, regional shares, competitors with a demineralized bone matrix market share, detailed demineralized bone matrix market segments, market trends and opportunities, and any further data you may need to thrive in the demineralized bone matrix industry. This demineralized bone matrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The demineralized bone matrix market consists of sales of puros demineralized bone matrix, bio-demineralized bone matrix (DBM), evograft, demineralized bone matrix chips, and demineralized bone matrix sheets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.